TY - JOUR
T1 - Effects of growth hormone treatment in adults with Prader-Willi syndrome
AU - Butler, M G
AU - Smith, B K
AU - Lee, Jae Hoon
AU - Gibson, C A
AU - Schmoll, C
AU - Moore, W V
AU - Donnelly, J E
PY - 2013
Y1 - 2013
N2 - Context: Beneficial effects of growth hormone (GH) treatment are reported in children with Prader-Willi syndrome (PWS) but limited data on treating PWS adults with GH.
Objective: Our objective is to examine the effects of GH on body composition, physical activity and energy balance, diet, general chemistry and endocrine measures and quality of life in PWS adults.
Design and Patients: We studied body composition, energy expenditure, physical activity, strength, quality of life and blood chemistry and endocrine measures in 11 adults with PWS (6F:5M; average age = 32 yrs) over a 2 year interval with GH treatment during the first year only. The data were analyzed using linear modeling.
Main Outcome Measures: Electrolyes, IGF-I, glucose, thyroid, insulin, lipids, body composition, physical activity and strength, diet, energy expenditure and quality of life data were collected at baseline, at 12 months during GH therapy and at 24 months after GH treatment cessation at 12 months.
Resu
AB - Context: Beneficial effects of growth hormone (GH) treatment are reported in children with Prader-Willi syndrome (PWS) but limited data on treating PWS adults with GH.
Objective: Our objective is to examine the effects of GH on body composition, physical activity and energy balance, diet, general chemistry and endocrine measures and quality of life in PWS adults.
Design and Patients: We studied body composition, energy expenditure, physical activity, strength, quality of life and blood chemistry and endocrine measures in 11 adults with PWS (6F:5M; average age = 32 yrs) over a 2 year interval with GH treatment during the first year only. The data were analyzed using linear modeling.
Main Outcome Measures: Electrolyes, IGF-I, glucose, thyroid, insulin, lipids, body composition, physical activity and strength, diet, energy expenditure and quality of life data were collected at baseline, at 12 months during GH therapy and at 24 months after GH treatment cessation at 12 months.
Resu
M3 - Article
SP - 81
EP - 87
JO - Growth Hormone & IGF Research
JF - Growth Hormone & IGF Research
ER -